drugset / Trial / NCT05184192

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192

Phase 2 Completed 68 enrolled Washington University School of Medicine
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will investigate the efficacy of oral gabapentin in olfactory improvement following Covid-19- associated olfactory dysfunction. This is a randomized, double-blinded, placebo-controlled trial.

Timeline

Start
2022-01-10
Primary completion
2023-08-29
Completion
2023-08-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule Oral